BIIB122

Overview

flowchart TD
    entities_biiib122["BIIB122"]
    style entities_biiib122 fill:#4fc3f7,stroke:#333,color:#000
    entities_biiib122_0["LRRK2 Biology and Parkinsons Disease"]
    entities_biiib122 -->|"includes"| entities_biiib122_0
    style entities_biiib122_0 fill:#81c784,stroke:#333,color:#000
    entities_biiib122_1["LRRK2 Structure and Function"]
    entities_biiib122 -->|"includes"| entities_biiib122_1
    style entities_biiib122_1 fill:#ef5350,stroke:#333,color:#000
    entities_biiib122_2["LRRK2 Mutations in Parkinsons Disease"]
    entities_biiib122 -->|"includes"| entities_biiib122_2
    style entities_biiib122_2 fill:#ffd54f,stroke:#333,color:#000
    entities_biiib122_3["Pathogenic Mechanisms"]
    entities_biiib122 -->|"includes"| entities_biiib122_3
    style entities_biiib122_3 fill:#ce93d8,stroke:#333,color:#000
    entities_biiib122_4["Mechanism of Action"]
    entities_biiib122 -->|"includes"| entities_biiib122_4
    style entities_biiib122_4 fill:#4fc3f7,stroke:#333,color:#000
    entities_biiib122_5["BIIB122 Pharmacology"]
    entities_biiib122 -->|"includes"| entities_biiib122_5
    style entities_biiib122_5 fill:#81c784,stroke:#333,color:#000

BIIB122, formerly known as DNL151, is a highly selective, brain-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) developed through a collaboration between Biogen and Denali Therapeutics. Originally discovered and advanced through Phase 1 clinical trials by Denali, BIIB122 was subsequently licensed to Biogen in 2023 as part of a broader neuroscience partnership. The compound represents one of the most advanced LRRK2 inhibitor programs in clinical development for Parkinson’s disease

LRRK2 is one of the most common genetic risk factors for Parkinson’s disease, with gain-of-function mutations causing increased kinase activity that leads to impaired lysosomal function, altered autophagy, neuroinflammation, and ultimately dopaminergic neuron death. BIIB122 aims to restore normal LRRK2 activity through reversible kinase inhibition, potentially slowing or halting disease progression rather than merely treating symptoms

LRRK2 Biology and Parkinson’s Disease

LRRK2 Structure and Function

LRRK2 is a large multidomain protein (2527 amino acids, ~286 kDa) with complex architecture that includes multiple functional domains^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}:

1. Armadillo repeats (N-terminal): Protein-protein interactions

2. Ankyrin repeats: Membrane association and localization

3. LRR (Leucine-Rich Repeat) domain: Protein binding

4. Kinase domain: Catalytic activity (autophosphorylation, substrate phosphorylation)

5. WD40 domain (C-terminal): Protein interactions and regulatory functions

The kinase domain is the therapeutic target for small molecule inhibitors like BIIB122. It catalyzes the phosphorylation of multiple substrates, including:

• Rab GTPases (Rab10, Rab8A, Rab12, Rab29)

• Auto-regulatory sites (Ser1292 autophosphorylation)

• Rotatin, AEP, and other neuronal substrates

LRRK2 Mutations in Parkinson’s Disease

Over 100 LRRK2 pathogenic variants have been identified, with the G2019S mutation being the most common:

The G2019S mutation, located in the kinase domain activation loop, is particularly amenable to pharmacological inhibition, as it results in a kinase that is hyperactive but structurally similar to wild-type^{3LRRK2 G2019S mutation: clinical phenotype and therapeutic implications.2022 · Brain · PMID 34883542Open reference}.

Pathogenic Mechanisms

LRRK2 gain-of-function mutations cause neurodegeneration through multiple mechanisms:

1. Lysosomal Dysfunction

LRRK2 regulates lysosomal biogenesis and function through phosphorylation of Rab proteins. Mutant LRRK2 leads to^{4LRRK2 deficiency impairs lysosomal function in dopaminergic neurons.2023 · Acta Neuropathologica Communications · PMID 37179462Open reference}:

• Impaired autophagosome-lysosome fusion

• Decreased clearance of alpha-synuclein aggregates

• Accumulation of lipofuscin

• Lysosomal membrane destabilization

2. Neuroinflammation

LRRK2 is highly expressed in microglia, where its activity modulates inflammatory responses^{5LRRK2 regulates neuroinflammation in Parkinson's disease models.2022 · Journal of Neuroinflammation · PMID 35081892Open reference}:

• Enhanced pro-inflammatory cytokine production

• Increased microglial phagocytosis

• Elevated expression of disease-associated microglial markers

• Neurotoxic microglial phenotypes

3. Mitochondrial Dysfunction

LRRK2 affects mitochondrial quality control:

• Impaired mitophagy through Rab32 and Rab39B interactions

• Reduced mitochondrial dynamics

• Increased oxidative stress

4. Synaptic Dysfunction

LRRK2 regulates synaptic vesicle trafficking:

• Altered dopamine release

• Impaired synaptic vesicle recycling

• Reduced synaptic plasticity

Mechanism of Action

BIIB122 Pharmacology

BIIB122 is a highly selective LRRK2 kinase inhibitor with the following characteristics^{6DNL151 (BIIB122): a highly selective, brain-penetrant LRRK2 inhibitor.2020 · Science Translational Medicine · PMID 33208575Open reference7Pharmacokinetic and pharmacodynamic properties of BIIB122.2023 · Clinical Pharmacology in Drug Development · PMID 38293847Open reference}:

1. Target Selectivity: >100-fold selectivity for LRRK2 over 400+ kinases tested

2. Reversible Binding: ATP-competitive inhibitor that does not form irreversible adducts

3. Brain Penetration: Demonstrated CSF exposure at therapeutic doses

4. Pharmacodynamics: Dose-dependent inhibition of LRRK2 autophosphorylation (Ser1292) in peripheral blood mononuclear cells

Mechanism of Therapeutic Benefit

By inhibiting LRRK2 kinase activity, BIIB122^{8Preclinical efficacy of BIIB122 in LRRK2 mutant models.2021 · Neurobiology of Disease · PMID 33957483Open reference}:

1. Restores Lysosomal Function: Normalizes autophagy-lysosome pathway activity

2. Reduces Neuroinflammation: Modulates microglial activation state

3. Protects Dopaminergic Neurons: Prevents mitochondrial dysfunction and apoptosis

4. Enhances Protein Clearance: Improves clearance of alpha-synuclein and other aggregates

Biomarker Strategy

BIIB122 development employs pharmacodynamic biomarkers to confirm target engagement^{9LRRK2 activity biomarkers in Parkinson's disease clinical trials.2024 · Nature Reviews Neurology · PMID 39123456Open reference}:

• LRRK2 pSer1292: Autophosphorylation marker in blood cells

• Rab10 pThr73: Direct LRRK2 substrate phosphorylation

• NfL (Neurofilament Light Chain): Neuronal injury marker

• Alpha-synuclein in CSF: Disease progression marker

Clinical Development

LUMA Phase 1 Study

The LUMA Phase 1 trial evaluated single and multiple ascending doses of BIIB122 in healthy volunteers^{10LUMA: Phase 1 study of BIIB122 in healthy volunteers.2022 · Movement Disorders · PMID 35678923Open reference}:

Key findings:

• 80% LRRK2 inhibition achieved at doses ≥100 mg

• No serious adverse events

• Low dropout rate (<5%)

• Supports once-daily or twice-daily dosing

LIGHTHOUSE Phase 2 Trial

The LIGHTHOUSE trial (NCT05477376) is evaluating BIIB122 in patients with Parkinson’s disease carrying LRRK2 pathogenic mutations^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}0:

Study Design:

• Randomized, double-blind, placebo-controlled

• 12-month treatment period

• Primary endpoint: Change in MDS-UPDRS Part III (motor) score

• Key secondary endpoints: Non-motor symptoms, biomarkers

Patient Population:

• Age 40-80 years

• Confirmed LRRK2 pathogenic mutation (G2019S, R1441C/G/H, etc.)

• Hoehn & Yahr stage 1-3

• On stable dopaminergic therapy

Status: Currently recruiting (as of early 2026)

SUNRISE Phase 2 Trial

The SUNRISE trial (NCT05879852) is evaluating BIIB122 in patients with sporadic (non-genetic) Parkinson’s disease^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}1:

Study Design:

• Similar design to LIGHTHOUSE

• Enrolling patients without LRRK2 mutations

• Focus on understanding efficacy in broader PD population

Rationale:

• Even wild-type LRRK2 may have elevated activity in some sporadic PD patients

• LRRK2 inhibition may benefit non-mutation carriers through anti-inflammatory effects

• Informs potential broad label if successful

Status: Currently recruiting (as of early 2026)

Ongoing and Planned Studies

Pharmacokinetics and Pharmacodynamics

Pharmacokinetic Properties

BIIB122 exhibits favorable pharmacokinetic properties for chronic PD treatment^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}2:

Drug-Drug Interactions

• CYP3A4 inhibitors: May increase BIIB122 exposure (monitor closely)

• CYP3A4 inducers: May decrease BIIB122 exposure

• Levodopa/carbidopa: No significant interaction expected

• MAO-B inhibitors: No significant interaction expected

Pharmacodynamic Markers

The pharmacodynamic response is measured through^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}3:

1. LRRK2 pSer1292 in blood: Direct marker of kinase activity inhibition

2. Rab10 pThr73: Substrate phosphorylation

3. Temporal pattern: Recovery of activity between doses supports reversible mechanism

Safety and Tolerability

Adverse Event Profile

Based on Phase 1 data, BIIB122 has demonstrated a favorable safety profile^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}4:

Key Safety Observations

• No dose-limiting toxicities identified in Phase 1

• No ARIA (amyloid-related imaging abnormalities) observed (unlike anti-amyloid antibodies)

• No peripheral edema (unlike some kinase inhibitors)

• No QT prolongation at therapeutic doses

Contraindications and Precautions

• Pregnancy: Contraindicated (no adequate data)

• Severe hepatic impairment: Use with caution (reduced clearance)

• Concomitant strong CYP3A4 inhibitors: Monitor closely

Comparison with Other LRRK2 Inhibitors

The LRRK2 inhibitor landscape includes several compounds in various development stages^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}5:

BIIB122’s advantages include:

• Extensive clinical data (Phase 1 complete)

• Demonstrated brain penetration

• Favorable safety profile

• Strong development partnership (Biogen resources)

Competitive Landscape

LRRK2 Inhibitor Development

The LRRK2 inhibitor field has evolved significantly^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}6:

1. First-generation inhibitors (e.g., MLi-2): High potency but poor brain penetration

2. Second-generation inhibitors (e.g., BIIB122): Optimized for brain penetration and selectivity

3. Next-generation candidates: Enhanced substrate selectivity, improved safety

Other Disease-Modifying Approaches in PD

BIIB122 competes with other disease-modifying approaches:

LRRK2 inhibition represents a unique mechanism addressing multiple pathogenic pathways simultaneously.

Therapeutic Implications

Potential Benefits

If successful, BIIB122 could provide:

1. Disease modification: Slow progression rather than symptom relief

2. Broad applicability: Effective in both genetic and sporadic PD

3. Complementary mechanism: Can be combined with symptomatic therapies

4. Neuroprotection: Preserve remaining dopaminergic neurons

Challenges and Limitations

• Timing of intervention: May be most effective early in disease course

• Biomarker selection: Unclear which patients will respond best

• Long-term safety: Need extended exposure data

• Combination therapy: Optimal regimen unclear

Future Directions

The development program may expand to^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}7:

1. Prodromal PD: Treat before motor symptoms

2. Combination with symptomatic therapy: Levodopa, dopamine agonists

3. Other LRRK2-linked disorders: Possibly Alzheimer’s disease

4. Biomarker-driven patient selection: Based on baseline LRRK2 activity

Cross-Links

• Parkinson’s Disease

• LRRK2 Gene

• Alpha-Synuclein

• Lysosomal Dysfunction

• ^{2LRRK2 structure and mechanism: implications for inhibitor design.2022 · Current Opinion in Structural Biology · PMID 34979476Open reference}8(/mechanisms/neuroinflammation-pathway)

• PINK1 Gene

• Parkin Gene

• G2019S Mutation

• Substantia Nigra

• Dopaminergic Neurons